Ascentage Pharma plans board meeting on results

Ascentage Pharma Group International filed a Form 6-K as a foreign private issuer, furnishing a Hong Kong announcement that its Board will hold a meeting on Wednesday, August 19, 2026.

Rhea-AI Filing Summary

Ascentage Pharma Group International filed a Form 6-K as a foreign private issuer, furnishing a Hong Kong announcement that its Board will hold a meeting on Wednesday, August 19, 2026. The Board will consider, among other matters, approving the Group’s unaudited interim results for the six months ended June 30, 2026 and their publication.

The announcement also lists the current Board composition, including an executive Chairman, non-executive Directors and several independent non-executive Directors, reflecting the company’s governance structure.

Key Figures

Board meeting date: August 19, 2026 Interim reporting period: Six months ended June 30, 2026 Announcement date: August 5, 2026

3 metrics

Board meeting date August 19, 2026 Date of the Board meeting to consider unaudited interim results

Interim reporting period Six months ended June 30, 2026 Period for which the Group’s unaudited interim results will be considered

Announcement date August 5, 2026 Date Ascentage Pharma announced the upcoming Board meeting

Key Terms

Report of Foreign Private Issuer, unaudited interim results, independent non-executive Directors, limited liability

4 terms

Report of Foreign Private Issuer regulatory

"Form 6-K Report of Foreign Private Issuer pursuant to Rule 13a-16"

A report of a foreign private issuer is a formal filing that a non‑U.S. company makes to U.S. regulators to share important business, financial, or governance information with American investors. Think of it as a regular update or press packet that keeps investors informed about events that could change a company’s value—like earnings, management changes, contracts, or regulatory developments—so investors can make timely, informed decisions.

unaudited interim results financial

"considering and, if appropriate, approving the unaudited interim results of the Group"

Financial statements covering a company’s short-term reporting period (such as a quarter or half-year) that have been prepared by management but have not been independently examined by external auditors. They give investors a timely snapshot of revenue, profit and cash flow between annual reports, but carry less assurance than audited accounts because the numbers may be adjusted later or contain errors; think of them as a vetted draft rather than a final, certified report.

independent non-executive Directors regulatory

"Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors"

Independent non-executive directors are board members who do not work for the company and have no significant financial or personal ties to its managers; they do not run day-to-day operations but attend board meetings to oversee strategy and decisions. For investors, they matter because they act like outside referees or impartial advisors who help prevent self-dealing, challenge management when needed, and boost confidence that the company’s decisions serve shareholders’ interests.

limited liability regulatory

"(Incorporated in the Cayman Islands with limited liability)"

FAQ

What does Ascentage Pharma (AAPG) disclose in this Form 6-K?

Ascentage Pharma Group International discloses that its Board will meet on August 19, 2026 to consider, among other items, approving the Group’s unaudited interim results for the six months ended June 30, 2026 and their publication via a Hong Kong announcement.

When is the Ascentage Pharma (AAPG) Board meeting scheduled?

The Board meeting is scheduled for Wednesday, August 19, 2026. At this meeting, directors plan to review and, if appropriate, approve the Group’s unaudited interim financial results for the six-month period ended June 30, 2026 and address related matters.

Which financial period will Ascentage Pharma (AAPG) review at the meeting?

The Board will consider the Group’s unaudited interim results for the six months ended June 30, 2026. This covers the first half of 2026 and is intended to support the preparation and publication of interim financial information for shareholders and the market.

On which exchange is Ascentage Pharma (AAPG) listed according to the notice?

The notice states that Ascentage Pharma Group International is listed on The Stock Exchange of Hong Kong Limited with Stock Code: 6855. The attached announcement follows the Hong Kong listing rules and includes standard exchange responsibility disclaimers.

Who leads the Board of Ascentage Pharma (AAPG) as referenced in the notice?

The Board is led by Dr. Yang Dajun, who serves as Chairman and Executive Director. The notice also identifies additional non-executive and independent non-executive Directors, outlining the broader governance structure overseeing Ascentage Pharma Group International and its subsidiaries.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 09:17 AM Accepted by SEC EDGAR 08/05/2026 - 09:16 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of August 2026

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

On August 5, 2026, Ascentage Pharma Group International issued an announcement dated August 5, 2026 entitled “Notice of Board Meeting”. A copy of the announcement is furnished as Exhibit 99.1.

1

INDEX TO EXHIBITS

Exhibit
Number		Exhibit Title
99.1		Announcement date August 5, 2026

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: August 5, 2026	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

3

Exhibit 99.1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

NOTICE OF BOARD MEETING

The board of directors (the “Board”) of Ascentage Pharma Group International (the “Company”, together with its subsidiaries, collectively the “Group”) hereby announces that a meeting of the Board will be held on Wednesday, August 19, 2026, for the purpose of, among other things, considering and, if appropriate, approving the unaudited interim results of the Group for the six months ended June 30, 2026 and its publication.

By order of the Board

Ascentage Pharma Group International

Dr. Yang Dajun

Chairman and Executive Director

Suzhou, People’s Republic of China, August 5, 2026

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon DazhongNote 1 as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky ^{Note 2}, Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors.

Notes:

1. Dr. Lu Simon Dazhong satisfy the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance requirements.

2. Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 ANNOUNCEMENT DATE AUGUST 5, 2026 5.5 KB